- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
Hospital-Based Strategy Lowers Risk of Death in Patients with Acute Heart Failure
November 05, 2022
Risk stratification in the emergency department led to a 12% lower risk of death from any cause or hospitalization for cardiovascular causes compared with usual care.
Finding the Optimal Role for Omecamtiv Mecarbil in HFrEF, with Nihar Desai, MD, MPH
November 05, 2022
Nihar Desai, MD, MPH, discusses the results of a study presented at AHA 22 examining the potential impact of omecamtiv mecarbil use on outcomes and healthcare resource utilization based on data from the GALACTIC-HF trial.
Torsemide Provides No Benefit Over Furosemide for Mortality, Hospitalization in Heart Failure
November 05, 2022
Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.
COVID-19 Donor Hearts Still Viable for Transplantation, Study Finds
October 31, 2022
An analysis of data from the United Network for Organ Sharing database, which included the first 84 COVID-19-positive heart transplants, indicates hearts from COVID-19-positive donors were still viable for transplant and not associated with increased risk of organ failure rate, risk of postoperative stroke or dialysis, and 30-day mortality.
Cardiology Month in Review: October 2022
October 29, 2022
The October 2022 cardiology month in review features the top content from HFSA 2022, new data related to antithrombotic therapy in atrial fibrillation, and shining a spotlight on the AHA’s scientific statement on patient-reported outcomes in peripheral artery disease.
County-Level Food Insecurity Linked to Increased Heart Failure Mortality Rates
October 26, 2022
An analysis of data from more than 2900 counties in the US is providing clinicians with new insight into the impact of social determinants of health, namely food insecurity, might influence heart failure mortality rates on a population level across the US.
Black Patients with Heart Failure Half as Likely to Receive Device Therapy, Transplant as White Patients
October 19, 2022
Despite no differences in patient preferences, an analysis from the National Institutes of Health suggests Black patients with heart failure were 55% less likely than their White counterparts to receive a ventricular assist device or transplantation.
Furosemide Injection Could Improve Congestion Management in Heart Failure Without Need for Hospitalization
October 07, 2022
Data from the AT-HOME HF pilot study presented at HFSA 2022 provide insight into the effects of furosemide injection 8 mg/mL on congestion management among patients with heart failure ahead of the agent's October 8 PDUFA date.
Trends in Device Therapy for Heart Failure, with Andrew Sauer, MD
October 06, 2022
At HFSA 2022, Andrew Sauer, MD, provides perspective on contemporary trends in device therapy in heart failure, including recommendations made within the 2022 ACC/AHA/HFSA heart failure guidelines.
8-in-10 Medicare Beneficiaries Hospitalized with HFpEF Could be Considered Candidates for Dapagliflozin
October 04, 2022
An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.